VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG have announced initial positive results from their strategic research collaboration aimed at developing next-generation antibody oligonucleotide conjugates (AOCs) for autoimmune and chronic immune diseases. The early in vitro studies demonstrated that an AOC candidate combining the companies' technologies exhibited greater potency than the equivalent unconjugated oligonucleotide, suggesting that the approach can selectively deliver therapeutic oligonucleotides to disease-specific cells.
This milestone is significant as it validates the potential of AOCs to enhance the efficacy of oligonucleotide-based therapies by directing them to target cells, thereby reducing off-target effects and improving therapeutic outcomes. The collaboration leverages VERAXA's proprietary click chemistry-powered conjugation technology, which is being applied beyond its primary focus on solid tumors, and Secarna's expertise in antisense oligonucleotide discovery and development.
According to the companies, they are currently discussing next steps in the collaboration. This progress is a testament to the potential of combining innovative technologies to address unmet medical needs in autoimmune and chronic immune diseases. The positive results also underscore the versatility of VERAXA's platform, which is already being used in developing bispecific T cell engagers and bispecific antibody-drug conjugates (ADCs), as well as its proprietary BiTAC formats.
VERAXA Biotech was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution for life science research. The company is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, guided by rigorous quality-by-design principles. Secarna Pharmaceuticals is a leading company in the field of antisense oligonucleotide therapeutics, with a strong pipeline and platform.
The successful early results from this collaboration could pave the way for new treatment options for patients suffering from autoimmune and chronic immune diseases, which are often debilitating and have limited therapeutic options. By improving the delivery and potency of oligonucleotide drugs, this approach may offer a more targeted and effective treatment strategy.
Investors and industry observers will be watching closely as the collaboration progresses, as it could lead to significant advancements in the field of AOCs. For more information about VERAXA Biotech, visit their newsroom at http://ibn.fm/VRXA.
